Life Molecular Imaging
  • Home
  • About
    • Our Mission
    • Our History
    • Our Partners
    • Compliance & Code of Conduct
  • Innovation
    • Neuroimaging
    • Cardiovascular Imaging
    • Pharma Collaborations
  • Products
    • Neuraceq®
  • Clinical Trials
    • Advance study
    • Cardiag Study
    • Expanded Access Program
  • Careers
  • News
    • Press Releases
    • Selected Publications
  • Contact
Life Molecular Imaging
  • Home
  • About
    • Our Mission
    • Our History
    • Our Partners
    • Compliance & Code of Conduct
  • Innovation
    • Neuroimaging
    • Cardiovascular Imaging
    • Pharma Collaborations
  • Products
    • Neuraceq®
  • Clinical Trials
    • Advance study
    • Cardiag Study
    • Expanded Access Program
  • Careers
  • News
    • Press Releases
    • Selected Publications
  • Contact
NEWS

Life Molecular Imaging announces an ongoing collaboration with UCB for
PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive
Supranuclear Palsy

March 3, 2021

LEARN MORE
NEWS

Life Molecular Imaging is Proud to Support the New IDEAS Study to Further
Demonstrate the Value of Amyloid PET for Diagnosing Alzheimer’s Disease
in Diverse Communities

December 11, 2020

LEARN MORE
NEWS

Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy

July 7, 2020

LEARN MORE
NEWS

Life Molecular Imaging announces presentation of new scientific data at the Human Amyloid Imaging Meeting

Januray 15, 2020

LEARN MORE
  • 1
  • 2
  • 3
  • 4
  • 5